NEW YORK, Feb. 18 (GenomeWeb News) - Eclipse Diagnostics, Large Scale Biology's new diagnostics subsidiary that plans to market mass spec-based pattern recognition technology, announced its management team yesterday.
Kevin Ryan, president and CEO of LSBC, will also serve as Eclipse's president. He holds a bachelor degree in business and marketing from the University of Notre Dame.
John Rakitan will be the company's senior vice president and general manager, in addition to being senior vice president, general counsel, and secretary at LSBC. Rakitan holds a JD from the University of Notre Dame and a BS in biology from Northern Illinois University.
Gary Wolfe will serve as Eclipe's senior vice president and CSO. He has been working for LSBC since 1999. Wolfe received a BS in chemistry from the University of California, Los Angeles, and a PhD in physical chemistry from the University of Washington.
Guy della Cioppa will be the company's senior vice president for business development. He joins Eclipse from NanoInk, where he was executive vice president of business development. Prior to that, he worked for LSBC. He holds a PhD in biology from the University of California, Los Angeles.
Ronal Artale will serve as the company's senior vice president and CFO. He is also senior vice president, COO, and CFO at LSBC. Artale holds an MBA in finance from St. John's University.
In addition, John Chute has been appointed to Eclipse's scientific advisory board. He is a medical oncologist and hematologist and an associate professor at the Duke University Medical Center. Prior to that, he was vice president for medical affairs at LSBC. Chute holds an undergraduate degree from the University of Notre Dame and a medical degree from Georgetown University School of Medicine.
Structural proteomics company Shamrock Structures of Woodrige, Ill., announced its scientific advisory board yesterday. Coming on board are: Michael Johnson, a professor of medicinal chemistry and pharmacognosy at the University of Illinois at Chicago (UIC); Richard Morimoto, a professor of biology at Northwestern University; Andrew Mesecar, an assistant professor of medicinal chemistry and pharmacognosy at UIC; Bernard Santarsiero, a research professor at UIC and a co-founder of Syrrx; and Richard van Breemen, a professor of medicinal chemistry and pharmacognosy at UIC.
Rino Rappuoli has become CSO of Chiron, the company said yesterday. He had been Chiron's acting CSO, as well as vice president for vaccines research. Rappuoli joined the company in 1992, when Chiron acquired Italian vaccines company Sclavo, where he was head of research and development. Rappuoli holds a doctoral and a bachelor's degree in biological sciences from the University of Siena in Italy.
Thomas Schweins has become vice president for corporate strategy of Qiagen. He joins the company from The Boston Consulting Group, where he was a manager in Germany. Schweins holds a PhD from the Max Planck Society, an MSc in business administration and chemistry from the University of Southern California Los Angeles, and an undergraduate degree in biochemistry from the University of Hanover in Germany.
Douglas Powell has become director of immunobiology at Antigen Express, a subsidiary of Generex Biotechnology, the company said last week. He joins the company from Millennium Pharmaceuticals, where he was a senior scientist. Powell holds a PhD in genetics from George Washington University.
James Golden III has become vice president for research at Life Science Insights, the company said today. Framingham, Mass.-based Life Science Insights, part of IDC, offers research to life science companies. Golden joins the company from CuraGen-spinout 454 Life Sciences, where he was business development manager. Golden received a PhD in mechanical engineering from Vanderbilt University, an MS in computer science from the University of Tennessee, and a bachelor's degree in mathematics from Rhodes College.
Vaughn Kailian has become chairman of the board of Cambridge, Mass.-based Elixir Pharmaceuticals, the company said today. He is also vice chair of the board of directors of Millennium Pharmaceuticals. Prior to joining Millennium, he was CEO of COR Therapeutics until it was acquired by Millennium. Kailian holds a BA from Tufts University.
David Reiter has become vice president, general counsel, and corporate secretary of Luminex, the company said yesterday. Previously, he was general counsel for 724 Solutions and senior counsel for Compaq Computer.
Goran Ando has joined the board of directors of Decode Genetics, the company said last week. He is the CEO of proteomics company Celltech, which he joined last year from Pharmacia, where he was executive vice president and president of R&D.
V. William Hunt has joined the board of directors of Brightpoint of Plainfield, Ind., the company said last week. He is chairman of Hunt Capital Partners, an Indianapolis-based venture capital and consulting firm. Hunt holds a JD and a BA from Indiana University and graduated from the Harvard Business School Advanced Management Program.
Harry Elias will join the board of directors of Bio-Reference Laboratories, the company said last week. He replaces Morton Topfer, who stepped down as director and vice chairman of Bio-Reference for personal reasons. Elias is chairman of JVC Company of America.
Andreas Manz has won the 2004 Jouan Robotics Award, the Association for Laboratory Automation said earlier this month. Manz is professor of analytical chemistry at the Institute of Spectrochemistry and Applied Spectroscopy in Dortmund, Germany. His award-winning project focused on the use of microfluidic chips for analytical chemistry applications. He received the award at this year's LabAutomation conference in San Jose, Calif.